Activation of Forkhead Box O Transcription Factors by Oncogenic BRAF Promotes p21cip1-Dependent Senescence

Peter L.J. de Keizer1, Leisl M. Packer2, Anna A. Szypowska1, Paulien E. Riedl-Polderman1, Niels J.F. van den Broek1, Alain de Bruin2, Tobias B. Dansen1, Richard Marais3, Arjan B. Brenkman1, and Boudewijn M.T. Burgering1

Abstract

Oncogene-induced senescence (OIS) is a potent tumor-suppressive mechanism that is thought to come at the cost of aging. The Forkhead box O (FOXO) transcription factors are regulators of life span and tumor suppression. However, whether and how FOXOs function in OIS have been unclear. Here, we show a role for FOXO4 in mediating senescence by the human BRAFV600E oncogene, which arises commonly in melanoma. BRAFV600E signaling through mitogen-activated protein kinase/extracellular signal-regulated kinase resulted in increased reactive oxygen species levels and c-Jun NH2 terminal kinase–mediated activation of FOXO4 via its phosphorylation on Thr223, Ser226, Thr447, and Thr451. BRAFV600E-induced FOXO4 phosphorylation resulted in p21cip1-mediated cell senescence independent of p16ink4a or p27kip1. Importantly, melanocyte-specific activation of BRAF V600E in vivo resulted in the formation of skin nevi expressing Thr223/Ser226-phosphorylated FOXO4 and elevated p21cip1. Together, these findings support a model in which FOXOs mediate a trade-off between cancer and aging.

Introduction

Activating mutations in the Ser/Thr kinase BRAF are observed in ~7% of all human tumors with high occurrence in thyroid carcinoma, colorectal cancer, ovarian cancer (1), and especially melanoma (~70%; ref. 2). The predominant BRAF mutation present in these cases is a substitution of Val600 for Gln (BRAFV600E), which causes increased downstream signaling toward mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK; ref. 2). Although BRAF-activating mutations initially stimulate proliferation, cell cycle progression is ultimately arrested through induction of senescence (3–5). Oncogene-induced senescence (OIS) can be facilitated through the individual activities of p16ink4a and p21cip1 (6, 7), and also in case of BRAFV600E, these cell cycle inhibitors are thought to regulate senescence (4, 8, 9).

Reactive oxygen species (ROS) propagate cellular signaling induced by growth factors and thereby regulate a variety of cellular processes including proliferation (10, 11). However, when ROS levels increase above a certain threshold, sometimes called oxidative stress, ROS react with and damage the cellular interior. Additionally, excessive ROS can induce cellular senescence (12), and as such, they are considered to accelerate aging and age-related pathologies (13, 14). ROS are known to signal to a plethora of downstream targets, and it is currently elusive which of these regulate the induction of senescence.

Forkhead box O (FOXO) transcription factors are the mammalian orthologues of the Caenorhabditis elegans protein DAF-16, which functions as an important determinant of life span (15). FOXOs were originally identified as downstream components of insulin/insulin-like growth factor signaling through phosphoinositide 3-kinase (PI3K) and protein kinase B (PKB/AKT; refs. 16, 17). In mice, FOXOs act as functionally redundant tumor suppressors (18), and in cell systems, FOXOs can either mediate apoptosis or quiescence in response to growth factor deprivation (19). In contrast to insulin signaling, which represses FOXO activity, cellular ROS can activate FOXOs (20, 21). Regulation of FOXOs by ROS occurs through numerous posttranslational modifications (22), rendering FOXOs sensors of cellular ROS (23). Consequently, FOXO activation increases resistance to oxidative stress through transcription of enzymes as MnSOD (24) and catalase (25) through a negative feedback loop. Increased FOXO activity is associated with longevity in model organisms (15).
and humans (26), which lends credit to the hypothesis that excessive ROS accelerate aging. Thus, FOXOs are regulated by ROS, play a role in both tumor suppression and aging, and thereby provide an important paradigm to understanding the relation between aging and disease such as cancer.

Materials and Methods

Additional information is available in Supplementary Materials and Methods.

Antibodies

The antibodies against FOXO4 (834), HA (12CA5), phosphorylated Thr447, and phosphorylated Thr391 have been described before (21, 27). The following antibodies were purchased: phosphorylated Thr283/Tyr185-c-Jun NH2-terminal kinase (JNK) and phosphorylated Thr202/Tyr204-ERK (Cell Signaling); Thr28-phosphorylated FOXO4 (Upstate); MnSOD (Stressgen); trimethyl-H3K9 and FOXO3a (Upstate); p27kip1 (BD Pharmingen); p16ink4a (ab-2; Neomarkers); p21cip1 (BD Pharmingen); p16ink4a (ab-2; Neomarkers); p21cip1 (M19), BRAF (C19), FOXO4 (N19), FOXO1 (N18), proliferating cell nuclear antigen (PCNA; PC10), and p53 (DO-1; Santa Cruz); and tubulin (Sigma). Antibodies against phosphorylated Thr223 and phosphorylated Thr233/Ser226 were generated by immunizing rabbits with the keyhole limpet hemocyanin–conjugated peptides CKAPKKKPSVLPAPPEGA-pT-PTSPVG and CKAPKKPSVLAPPEGAP-pT-PT-pS-PVG, respectively, wherein pT and pS present phosphorylated threonine and serine. Produced antibodies were subjected to positive and negative affinity purification according to the manufacturer’s protocol (Covance).

Results

Ectopic introduction of FOXO4 induces cellular senescence in BRAFV600E-expressing Colo829, A375, and SK-mel28 melanoma cells

To study the involvement of FOXOs in BRAFV600E-dependent cellular responses, we ectopically expressed FOXO4 in the human melanoma-derived cell line, Colo829, harboring an endogenous BRAFV600E mutation. This resulted in reduced colony formation along with diminished PCNA and BrdUrDd positivity (Fig. 1A) but without significant TUNEL staining (Supplementary Fig. S1).

FOXOs repress oxidative stress (21), and increased oxidative stress is suggested to cause cellular senescence (12). Surprisingly, however, ectopic FOXO4 expression rendered Colo829 cells positive for SA-β-GAL activity (Fig. 1B). Also detection of two other independent markers of senescence (4, 31), senescence-associated heterochromatin foci (SAHF) and H3K9-trimethylation, was significantly enhanced by FOXO4 (Fig. 1C), suggesting that this indeed is a senescence response. To exclude artifacts of a single cell type, we also expressed FOXO4 in other melanoma cell lines that express endogenous BRAFV600E, A375, and SK-Mel28, or wild-type BRAF, CHL, and PMWK. Whereas FOXO4 induced SA-β-GAL expression in A375 and SK-Mel28, no positivity was observed in CHL or PMWK cells (Supplementary Fig. S2 and data not shown).

Cellular ROS measurements with H2DCFDA

HEK293T cells were transfected with pcDNA3 or a plasmid encoding BRAFV600E (2 μg), in parallel with phage-puro (500 ng). At 16 hours posttransfection, cells were selected with 2 μg/mL puromycin for 36 hours and subsequently left untreated or pretreated for 24 hours with 4 μmol/L N-acetyl cysteine (NAC) or 10 μmol/L U0126, washed with PBS, and incubated for 10 minutes with 1 mL 10 μmol/L H2DCFDA (Invitrogen). Following recovery for 4 hours in medium with or without NAC or U0126, cells were pretreated with or without 200 μmol/L H2O2 for 45 minutes and collected by trypsinization. Centrifuged cells were incubated with 0.02 mg/mL propidium iodide (PI), and live cells were analyzed by FACS for DCF fluorescence. CHL and WM266.4 cells were treated similarly, but without puromycin and PI selection.

Colony formation assay and senescence-associated β-galactosidase staining

A14 or U2OS cells were transfected as indicated together with phage-puro (500 ng). At 24 hours posttransfection, cells were subjected to puromycin selection (2 μg/mL). Following 2.5 days of selection, one set of cells was lysed and analyzed by immunoblotting for protein expression. At 10 days posttransfection, cells were fixed in methanol and stained with 0.5% crystal violet in 25% methanol. Plates were dried, and colony formation was quantified by destaining in 10% acetic acid and measuring absorbance at 560 nm. CHL, PMWK, Colo829, and A375 cells were treated similarly but transfected with 500 ng FOXO4 and 250 ng phage-puro. Senescence-associated β-galactosidase (SA-β-GAL) staining was performed 9 days posttransfection as described (30).
Thus, in endogenous BRAFV600E-expressing Colo829, A375, and SK-Mel28 melanoma cells, expression of FOXO4 induces a growth arrest through cellular senescence.

**BRAFV600E induces phosphorylation of FOXO4 on JNK target sites.**

The MEK-ERK pathway is a primary signaling output for normal and oncogenic BRAF. In addition to MEK-ERK signaling, BRAFV600E expression is reported to promote activation of JNK (32) which we confirmed (Supplementary Fig. S3). Previously, we showed that FOXO4 is a JNK target and identified Thr447 and Thr451 through mutation analysis as a subset of the phosphorylated acceptor sites (21). We therefore wondered whether BRAFV600E could signal through JNK toward FOXO4 to promote senescence. To fully address this question, we first determined all possible JNK sites of *in vitro* phosphorylated FOXO4 by liquid chromatography–tandem mass spectrometry analysis (Supplementary Data). In addition to the previously characterized Thr447 and Thr451, this revealed two novel residues, Thr223 and Ser226 (Supplementary Fig. S4). We generated phosphospecific antisera against these sites, including dually phosphorylated Thr223/Ser226. *In vitro*
phosphorylation by JNK significantly increased detection of wild-type FOXO4 by these respective antisera, especially the newly discovered Thr223 and Ser226, whereas FOXO4-4A in which these residues are mutated to Ala (Fig. 2A) was not detected. This indicates that Thr223, Ser226, Thr447, and Thr451 are JNK-phosphorylated acceptor sites.

Because BRAFV600E signaling induces activation of both ERK and JNK, we next determined whether phosphorylation of the identified sites in cultured cells is mediated by either of these kinases. H2O2, which activates both, indeed resulted in the phosphorylation of Thr223 of FOXO4. Additionally, stimuli that exclusively activate either ERK [12-O-tetradecanoylphorbol-13-acetate (TPA) and epidermal growth factor] or JNK (anisomycin) showed that Thr223 phosphorylation correlates with activation of JNK, not ERK (Fig. 2B; Supplementary Fig. S5). In agreement with JNK activation, BRAFV600E induced a significant increase in phosphorylation of all JNK sites, but...
not on the PKB/AKT site Thr28 (Fig. 2C). Furthermore, treatment of cells with the JNK inhibitor SP600125 not only inhibited BRAFV600E-induced JNK autophosphorylation in a dose-dependent manner, but also Thr223 phosphorylation of FOXO4 (Supplementary Fig. S6). Together, these results indicate that BRAFV600E promotes JNK-mediated phosphorylation of FOXO4.

To address whether phosphorylation of FOXO4 on the JNK sites is required for FOXO4 to be able to induce senescence in BRAFV600E-expressing melanoma cells, we expressed the FOXO4-4A mutant next to wild-type FOXO4. FOXO4-4A neither significantly repressed colony formation nor induced SA-β-GAL positivity (Fig. 2D). In contrast, a mutant of FOXO4 that mimics phosphorylation on JNK sites, FOXO4-4E, induced a senescence response similar to wild-type FOXO4 (Fig. 2D). Altogether, these data indicate that FOXO4 is a downstream target of BRAFV600E through JNK-mediated phosphorylation and that phosphorylation on the JNK target sites is required for FOXO4 to promote senescence in response to BRAFV600E.

**BRAFV600E** signaling elevates cellular ROS levels, which promote FOXO4 phosphorylation by JNK

JNK activity is regulated through a large variety of signaling pathways, and we therefore next addressed the molecular mechanism through which BRAFV600E regulates JNK and thereby FOXO4 activity. Elevations in cellular ROS generated through H2O2 treatment of cells can directly invoke senescence (12), and senescence induction in, for instance, melanocytes has recently been correlated with increased ROS (33). Moreover, OIS can be bypassed by ROS scavenging compounds such as NAC (34, 35). Hence, we investigated the possibility that BRAFV600E signaling affects cellular ROS levels by loading cells with the ROS detecting probe H2DCFDA (DCF). BRAFV600E expression significantly increased cellular ROS levels as detected by DCF fluorescence (Fig. 3A). The BRAFV600E-induced increase in cellular ROS could be further increased by treatment with H2O2 (45 minutes, 200 μmol/L) but was impaired on preincubation with NAC. Downstream signaling through MEK seems at least partially required, because preincubation with the MEK inhibitor U0126 reduced DCF fluorescence. These data indicate that ectopic BRAFV600E expression leads to the generation of cellular ROS through downstream MEK signaling. In agreement herewith, melanoma cells expressing BRAFV600E showed higher basal ROS levels compared with wild-type BRAF-expressing cells (Supplementary Fig. S7). Elevations in ROS are sufficient for phosphorylation of FOXO4 by JNK, as treatment of cells with H2O2 resulted in a time-dependent increase of both JNK activation and Thr223 phosphorylation (Supplementary Fig. S8; Fig. 2B). Moreover, BRAFV600E-mediated JNK activation and FOXO4 phosphorylation were repressed on pretreatment of cells with NAC or U0126 (Fig. 3B).

Prolonged treatment with U0126 induces apoptosis in Colo829 cells (36), making it impossible to interpret the effect of this inhibitor on FOXO4-induced senescence. Therefore, Colo829 cells were treated with NAC to reduce cellular ROS. This resulted in reduced colony formation of Colo829 cells (Fig. 3C), most likely due to the fact that proliferation per se requires low amounts of ROS (14). Importantly, however, NAC impaired the ability of FOXO4 to induce senescence in these cells. Altogether, these data point to a pathway in which BRAFV600E induces FOXO4 phosphorylation by JNK through a MEK-regulated elevation of intracellular ROS, and in line with that, ROS are essential for FOXO4 to induce senescence in the presence of BRAFV600E.

**p21<sup>cip1</sup> mediates the cell cycle arrest and senescence response by BRAFV600E-FOXO4 signaling**

Next, we addressed the mechanism downstream of how FOXO4 promotes BRAFV600E-induced senescence. p27<sup>kip1</sup> is an important mediator of FOXO-induced G1 arrest and subsequent quiescence response in the absence of growth factors (19). Therefore, we reasoned a role for p27<sup>kip1</sup>. FOXO4-induced p27<sup>kip1</sup> expression, however, was counteracted rather than enhanced by coexpression of BRAFV600E (Fig. 4A; data not shown). Thus, we conclude that the FOXO4-mediated cell cycle arrest, in response to BRAFV600E signaling, is unlikely to be regulated through p27<sup>kip1</sup>.

Next, we addressed the importance of another cyclin-dependent kinase (CDK) inhibitor, p16<sup>ink4a</sup>, which has been implicated in senescence. p16<sup>ink4a</sup> levels do not seem to increase on FOXO4 and BRAFV600E coexpression (Fig. 4A; data not shown). Also, in Colo829 cells in which FOXO4 induces senescence (Fig. 1), a premature stop mutation is present in the CDKN2A gene resulting in loss of p16<sup>ink4a</sup> expression (37). These data also argue against involvement of p16<sup>ink4a</sup> in FOXO4-mediated OIS driven by BRAFV600E.

Because p21<sup>cip1</sup> and p16<sup>ink4a</sup> seem functionally redundant in OIS (6, 7, 9), we next analyzed a role for p21<sup>cip1</sup>. Interestingly, BRAFV600E cooperated with FOXO4 to induce p21<sup>cip1</sup> expression (Fig. 4A), and in correlation with the induction of senescence, FOXO4 expression increased p21<sup>cip1</sup> expression in Colo829 cells (Supplementary Fig. S9). Similar effects were observed on p21<sup>cip1</sup> mRNA expression determined by quantitative real-time PCR. Moreover, BRAFV600E and FOXO4 expression resulted in a synergistic activation of a luciferase-reporter gene driven by the p21<sup>cip1</sup> promoter (Fig. 4B). This level of synergy was also observed using a construct under a different FOXO-responsive promoter (i.e., MnSOD) and a synthetic promoter encompassing six optimal FOXO DBEs (6x DBE; Supplementary Fig. S10), suggesting that the cooperative induction indeed reflects increased FOXO activity.

As HA-FOXO4-4A did not induce senescence in Colo829 cells, whereas HA-FOXO4-4E did, we also determined the ability of these mutants to induce p21<sup>cip1</sup> transcription. In line with the lack of senescence induction, HA-FOXO4-4A, but not HA-FOXO4-4E, was significantly less capable of driving p21<sup>cip1</sup> transcription (Fig. 4C). These data indicate that BRAFV600E activates FOXO4 through JNK-mediated phosphorylation to promote p21<sup>cip1</sup> transcription, which in Colo829 cells correlates with the induction of senescence.

To address to what extent p21<sup>cip1</sup> is required for the FOXO4-induced cell cycle arrest and senescence in response to BRAFV600E signaling, we used short hairpin RNA (shRNA)-mediated knockdown of p21<sup>cip1</sup>. This impaired p21<sup>cip1</sup>...
expression induced by BRAFV600E-FOXO4 coexpression (Supplementary Fig. S11). Whereas BRAFV600E and FOXO4 together induced a strong G1 arrest as determined by FACS analysis, this effect was abolished on knockdown of p21cip1 (Fig. 4D). Because p21cip1 expression is elevated in FOXO4-induced senescence in Colo829 cells, we also addressed the effect of p21cip1 knockdown on the induction of senescence. Strikingly, FOXO4 expression did not induce SA-β-GAL staining in Colo829 cells on p21cip1 knockdown (Fig. 4D), indicating that p21cip1 is required in FOXO4-induced senescence in these cells. Altogether, these data show that FOXO4 is a downstream target of BRAFV600E that can facilitate a cell cycle arrest and OIS through regulation of p21cip1.

BRAFV600E regulates p21cip1 expression through MEK and ROS-dependent phosphorylation of FOXOs

Following our observations that suggest BRAFV600E-mediated JNK/FOXO4 activation runs through MEK-ROS signaling, we addressed the involvement of MEK and ROS in the regulation of p21cip1 and cell cycle arrest by BRAFV600E and FOXO4. Pretreatment of cells with either NAC, to reduce ROS (Fig. 5A), or U0126, to inhibit MEK (Fig. 5B), repressed JNK activation by BRAFV600E, phosphorylation of FOXO4 on the JNK target site Thr223, and the cooperative induction of p21cip1. Furthermore, whereas ectopic expression of FOXO4 in Colo829 cells significantly enhanced p21cip1 promoter activity, pretreatment of these cells with U0126 or NAC reduced this effect (Fig. 5C). This shows that JNK-mediated phosphorylation of FOXO4 and the concomitant activation of p21cip1 transcription are dependent on MEK activity and elevations in cellular ROS.

Next, we investigated the role of endogenous FOXOs in signaling from BRAFV600E toward p21cip1 transcription. High ectopic expression of BRAFV600E strongly induced p21cip1 promoter activity (ref. 8; Fig. 5D). This induction was abrogated on shRNA-mediated simultaneous depletion of endogenous FOXO1, 3a, and 4, whereas add-back of a FOXO4 shell.
mutant insensitive to shRNA-mediated knockdown (FOXO4-SM) was sufficient to rescue BRAF<sup>V600E</sup>-induced transactivation of the p21<sup>cip1</sup> promoter (Fig. 5D; Supplementary Fig. S12 and S13). Thus, endogenous FOXOs are essential for ectopic BRAF<sup>V600E</sup> to induce p21<sup>cip1</sup> transcription.

### Endogenous BRAF<sup>V600E</sup> regulates FOXO4 phosphorylation and p21<sup>cip1</sup> expression in cultured melanoma cells and in vivo

To further investigate the endogenous regulation of FOXO4 by oncogenic BRAF, we used a distinct human melanoma-derived cell line WM266.4 (BRAF<sup>V600D</sup>; Fig. 6A). WM266.4 cells are tumorigenic yet express very high levels of p21<sup>cip1</sup>. This, we reasoned, made them suitable to investigate the entire endogenous signaling cascade from oncogenic BRAF toward p21<sup>cip1</sup>. Like Colo829 and in agreement with hyperactive BRAF signaling, WM266.4 cells expressed a significant amount of active ERK and JNK. As for Colo829 cells, expression of p16<sup>ink4a</sup> was not detectable in this cell line (Fig. 6A; ref. 38). Small interfering RNA (siRNA)–mediated knockdown of BRAF in WM226.4 cells reduced ERK and JNK activity and, importantly, resulted in diminished p21<sup>cip1</sup> expression (Supplementary Fig. S14), arguing that the high p21<sup>cip1</sup> level in WM266.4 cells is indeed driven by the oncogenic BRAF. Treatment of WM266.4 cells with U0126 inhibited MEK activity and subsequent JNK activation, indicating that, indeed also in these cells, MEK signaling is essential for JNK activation by oncogenic BRAF (Fig. 6B). Interestingly, next to impaired p21<sup>cip1</sup> expression, the U0126-mediated repression of JNK reduced phosphorylation of endogenous FOXO4 on the JNK sites Thr<sup>223</sup> + Ser<sup>226</sup> and also siRNA-mediated knockdown of endogenous FOXOs reduced the p21<sup>cip1</sup> expression (Fig. 6B). U0126 further enhanced this reduction, probably reflecting incomplete knockdown of FOXOs by these siRNAs. Together, these experiments indicate that oncogenic BRAF can regulate p21<sup>cip1</sup> expression through phosphorylation of endogenous FOXOs by JNK, confirming the results we obtained in our overexpression studies.
Ultimately, to study the biological relevance of our observations in vivo, we used a \(Braf^{+/LSL-V600E};\) Tyr::CreERT2/+ mouse model, which expresses BRAFV600E in melanocytes off the endogenous \(Braf\) gene in a tamoxifen-inducible manner (39). As reported before, activation of BRAFV600E signaling induced melanocytic nevi within the dermis, composed of nests of pigmented epitheloid cells intermingled with whorls of lightly pigmented and amelanotic spindle cells (Supplementary Fig. S15). At the periphery of these melanocytic nevi, we observed multiple patches of darkly pigmented, large polygonal cells, interpreted as neoplastic melanocytes. \(p21^{cip1}\) expression was significantly expressed within these neoplastic melanocytes at the periphery of the BRAFV600E-induced nevi (Fig. 6C), and minor \(p21^{cip1}\) expression was detected in the less pigmented regions of the nevi and within epidermal layers. To investigate endogenous FOXO4 expression in the mouse skin, we developed novel monoclonal antisera. The antisera could immunostain ectopically expressed mouse HA-FOXO4 in Colo829 cells (Supplementary Fig. S16). When applied to the mouse skin sections, the antisera showed expression of endogenous FOXO4 in the mouse skin (Fig. 6C).

To determine the phosphorylation status of FOXO4 on the JNK target sites in the BRAFV600E-expressing skin samples, we used \(p1^{223}/S^{226}\) antisera. Detection with the \(p1^{223}/S^{226}\) antisera showed nuclear staining in unstimulated cells, including Colo829 (Supplementary Fig. S17; data not shown). Knock-down of endogenous FOXO4 reduced, although not abolished, the signal, showing the extent of specificity of this antisera for endogenous FOXO4. Importantly, endogenous \(Thr^{223}/Ser^{226}\) phosphorylation of FOXO4 was specifically enriched in the areas of the nevi that also showed \(p21^{cip1}\) staining (Fig. 6C). Thus, in line with the cell culture data, in vivo activation of oncogenic BRAF promotes nevi formation, i.e., senescence in vivo, which harbor phosphorylation of FOXO4 on the JNK target sites \(Thr^{223}/Ser^{226}\) and elevated \(p21^{cip1}\) expression within similar compartments.

Discussion

Here, we describe a role for FOXO4 in BRAFV600E-induced senescence. BRAFV600E activates FOXO4 through a MEK-ROS-JNK signaling cascade to induce \(p21^{cip1}\) expression.
and senescence (Fig. 6D). Senescence represents a barrier for tumor formation, and consequently, the melanoma-derived cells we have used de facto have bypassed this barrier. Irrespectively, in cell culture active FOXO represses this barrier, suggesting that FOXO inactivation is one of the requirements for senescence bypass. This conclusion is supported by data showing that, in mice, loss of PTEN and consequently reduced FOXO activity synergize with BRAFV600E to induce melanoma (40). Despite limitations in studying senescence in melanoma cell lines in culture, our histochemical analysis of lesions from BRAFV600E mice clearly suggests that in vivo FOXO and p21cip1 indeed function in the senescence response induced by BRAFV600E.

Oncogenes induce senescence through various mechanisms. Although HRAS is an upstream regulator of RAF, HRASG12V expression in primary melanocytes induces senescence through the ER-associated unfolded protein response, whereas oncogenic (B)RAF does not (32). This difference between RAS and RAF is also reflected in mice models in which BRAFV600E induces both melanocyte senescence and

Figure 6. Endogenous BRAFV600E regulates p21cip1 transcription through FOXO4 phosphorylation on the JNK target sites. A, characterization of WM266.4 (BRAFV600E) cells. CHL (wt BRAF), Colo829 (BRAFV600E), and WM266.4 (BRAFV600E) cells were lysed and analyzed by immunoblotting. Endogenous FOXO4 expression was determined after immunoprecipitation. B, left, U0126 abrogates JNK signaling, endogenous phosphorylation of FOXO4 on Thr223 + Ser226 and p21cip1 expression in WM266.4 cells. WM266.4 cells were untreated or treated for 24 h with 10 μmol/L U0126 and analyzed as in A). The phosphorylation status of endogenous FOXO4 was determined after immunoprecipitation. HC, heavy chain. Right, endogenous FOXOs regulate p21cip1 expression in WM266.4 cells. Lysates of WM266.4 cells transfected with scrambled siRNA or siRNA against FOXO1,3a and 4 (siFOXO) and untreated or treated for 24 h with 20 μmol/L U0126 were analyzed by immunoblotting. C, expression of p21cip1, total FOXO4, and Thr223/Ser226-phosphorylated FOXO4 is elevated in neoplastic regions of BRAFV600E-induced nevi. Top, skin sections of tamoxifen-treated Braf+/LSL-V600E; Tyr::CreERT2+/o mice were analyzed for background signal (second antibody only), p21cip1 expression, total FOXO4, and Thr223/Ser226-phosphorylated FOXO4. Higher magnifications of the nevus (arrowheads) are shown in the bottom. The top right shows undifferentiated nevi. The bottom right represents a magnification of epidermal staining from the bottom left. Untreated tissue did not typically show positive staining. D, model on the regulation of FOXO4 by BRAFV600E, resulting in p21cip1-mediated senescence. BRAFV600E signaling activates MEK. This, in turn, induces elevations in cellular ROS levels, thereby promoting activation of JNK. JNK subsequently phosphorylates FOXO4 and thereby promotes specific transcription of p21cip1, rather than p27kip1 or p16ink4a, and triggers a senescence response.
Thus, although p16ink4a fulfills an important role in the suppression of melanoma progression, it seems not to be essential for establishing senescence (see also ref. 4). Here, we show, is required for activation of FOXO4, p21cip1 transcription, and subsequent senescence. Together, these and our data suggest that, besides oncogene-specific pathways, increased ROS direct part of the senescence program, which may be more generic. Recently, RAS-induced senescence was shown to require a RAS-dependent negative feedback loop repressing PI3K-PKB/AKT activity (42). As ROS, reduced PKB/AKT activity also activates FOXO, suggesting that activation of FOXO is the general event in senescence rather than the ROS/JNK signaling mechanism. Interestingly, the idea that FOXO activation will be a general component of senescence onset is in agreement with the current notion that the reverse, i.e., FOXO inactivation, represents a general component of tumor onset (18).

Mechanisms of senescence induction also greatly differ between cell types. In cell culture, melanocyte senescence differs from fibroblast senescence (discussed in ref. 43). Human melanocytes deficient in INK4a show an impaired senescence response, but INK4a-deficient human fibroblasts senesce normally. Because a number of families with inherited predisposition to melanoma showed loss of p16ink4a (44, 45), these and other data suggest that INK4a-dependent senescence is especially important in melanocytes. However, loss of p16ink4a is not very common in early-stage melanomas (46), and in oncogenic BRAF-positive human and mouse nevi, examples of cellular senescence in vivo p16ink4a expression are mosaic (47, 48). Also recently, we showed in the BrafV600E-LSL-INK4a, Tety:CreERT21/0 mouse model that loss of p16ink4a does not affect BRAFV600E-induced nevus formation (39). Furthermore, in these mice, BRAFV600E-induced melanoma showed nuclear p16ink4a staining in agreement with clinical data showing significant nuclear p16ink4a expression in primary melanoma (30%–85%) as well as metastatic melanoma (15%; ref. 48). Thus, although p16ink4a fulfills an important role in the suppression of melanoma progression, it seems not to be essential for establishing senescence (see also ref. 4). Here, we show firstly that, in the absence of p16ink4a, FOXO4 can induce senescence, and secondly, this requires p21cip1. This confirms the earlier suggestion that p21cip1 may facilitate melanocyte senescence in the absence of p16ink4a (5). Thus, in BRAFV600E signal-

References
8. Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M. RAF-induced proliferation or cell cycle arrest is determined by the level of RAF activity with arrest mediated by p21Cip1. Mol Cell Biol 1997;17:5598–611.


Activation of Forkhead Box O Transcription Factors by Oncogenic BRAF Promotes p21-Dependent Senescence

Peter L.J. de Keizer, Leisl M. Packer, Anna A. Szypowska, et al.

Cancer Res 2010;70:8526-8536. Published OnlineFirst October 19, 2010.

Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-10-1563

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2010/10/08/0008-5472.CAN-10-1563.DC1

Cited articles
This article cites 52 articles, 15 of which you can access for free at:
http://cancerres.aacrjournals.org/content/70/21/8526.full#ref-list-1

Citing articles
This article has been cited by 5 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/70/21/8526.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.